Spectrix Therapeutics Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 3

Employees
  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $249K

Spectrix Therapeutics General Information

Description

Developer of a proprietary formulation designed for the treatment of hypothyroidism. The company utilizes ion exchange resin to form a multi-particulate drug-resin complex and provides an enhanced drug release profile to increase efficacy and lessen side effects, enabling physicians to mimic a healthy thyroid's circadian release.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Pharmaceuticals
Primary Office
  • 4451 Dale Earnhardt Way
  • Unit D14
  • Northlake, TX 76262
  • United States
+1 (817) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spectrix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 03-Jun-2016 $249K 00000 Completed Startup
To view Spectrix Therapeutics’s complete valuation and funding history, request access »

Spectrix Therapeutics Patents

Spectrix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10874741-B2 Compound to treat sjogren's syndrome Active 28-Aug-2017 000000000 0
US-20210093574-A1 Compound to treat sjogren's syndrome Pending 28-Aug-2017 000000000
US-20190060462-A1 Compound to treat sjogren's syndrome Active 28-Aug-2017 000000000 0
AU-2020204558-A1 Compositions and methods of providing thyroid hormone or analogs thereof Pending 03-May-2016 0000000000
EP-3452077-A4 Compositions and methods of providing thyroid hormone or analogs thereof Pending 03-May-2016 A61K31/197 0
To view Spectrix Therapeutics’s complete patent history, request access »

Spectrix Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Mark Tengler Co-Founder & Chief Executive Officer
John Adams Jr. Co-Founder
John Dyett Co-Founder
To view Spectrix Therapeutics’s complete executive team members history, request access »

Spectrix Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial